Park Avenue Securities’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9M | Sell |
71,241
-9,174
| -11% | -$1.21M | 0.06% | 256 |
|
|
2026
Q1 | $11.2M | Sell |
80,415
-564
| -0.7% | -$79K | 0.09% | 177 |
|
|
2025
Q4 | $9.94M | Buy |
80,979
+2,163
| +3% | +$263K | 0.08% | 187 |
|
|
2025
Q3 | $8.75M | Buy |
78,816
+4,088
| +5% | +$465K | 0.07% | 215 |
|
|
2025
Q2 | $8.29M | Buy |
74,728
+34,195
| +84% | +$3.64M | 0.08% | 189 |
|
|
2025
Q1 | $4.54M | Buy |
40,533
+11,780
| +41% | +$1.22M | 0.06% | 217 |
|
|
2024
Q4 | $2.66M | Buy |
28,753
+6,878
| +31% | +$619K | 0.03% | 385 |
|
|
2024
Q3 | $1.83M | Sell |
21,875
-6,133
| -22% | -$468K | 0.02% | 455 |
|
|
2024
Q2 | $1.92M | Sell |
28,008
-7,433
| -21% | -$496K | 0.02% | 429 |
|
|
2024
Q1 | $2.6M | Sell |
35,441
-28,964
| -45% | -$2.23M | 0.03% | 329 |
|
|
2023
Q4 | $5.22M | Buy |
64,405
+8,079
| +14% | +$629K | 0.07% | 177 |
|
|
2023
Q3 | $4.22M | Buy |
56,326
+5,436
| +11% | +$418K | 0.07% | 178 |
|
|
2023
Q2 | $3.92M | Buy |
50,890
+2,684
| +6% | +$214K | 0.06% | 201 |
|
|
2023
Q1 | $4M | Sell |
48,206
-2,934
| -6% | -$243K | 0.07% | 177 |
|
|
2022
Q4 | $4.39M | Buy |
51,140
+12,303
| +32% | +$974K | 0.08% | 164 |
|
|
2022
Q3 | $2.4M | Buy |
38,837
+8,221
| +27% | +$518K | 0.05% | 225 |
|
|
2022
Q2 | $1.89M | Buy |
30,616
+14,694
| +92% | +$910K | 0.04% | 281 |
|
|
2022
Q1 | $947K | Buy |
15,922
+2,212
| +16% | +$141K | 0.02% | 504 |
|
|
2021
Q4 | $995K | Buy |
13,710
+1,438
| +12% | +$99K | 0.02% | 480 |
|
|
2021
Q3 | $857K | Buy |
12,272
+323
| +3% | +$22.7K | 0.02% | 476 |
|
|
2021
Q2 | $823K | Buy |
11,949
+1,001
| +9% | +$66.8K | 0.02% | 479 |
|
|
2021
Q1 | $708K | Buy |
10,948
+2,130
| +24% | +$137K | 0.02% | 475 |
|
|
2020
Q4 | $514K | Sell |
8,818
-55
| -0.6% | -$3.32K | 0.01% | 492 |
|
|
2020
Q3 | $561K | Sell |
8,873
-201
| -2% | -$13.9K | 0.02% | 406 |
|
|
2020
Q2 | $698K | Buy |
+9,074
| New | +$695K | 0.03% | 264 |
|
|
2020
Q1 | – | Sell |
-9,703
| Closed | -$631K | – | 402 |
|
|
2019
Q4 | $631K | Buy |
9,703
+380
| +4% | +$24.7K | 0.03% | 250 |
|
|
2019
Q3 | $591K | Buy |
+9,323
| New | +$609K | 0.03% | 223 |
|
|
2019
Q2 | – | Sell |
-3,222
| Closed | -$212K | – | 325 |
|
|
2019
Q1 | $212K | Buy |
+3,222
| New | +$214K | 0.01% | 429 |
|
|
2016
Q2 | – | Sell |
-2,418
| Closed | -$228K | – | 98 |
|
|
2016
Q1 | $228K | Buy |
+2,418
| New | +$218K | 0.04% | 71 |
|
Other funds holding GILD
Park Avenue Securities's GILD Position: Q2 2026 in Review
Park Avenue Securities reduced its Gilead Sciences (GILD) stake by 11% in Q2 2026, selling an estimated $1.21M and leaving 71,241 shares worth $9M. The position accounts for 0.06% of the portfolio, ranked #256.
Park Avenue Securities first reported a position in GILD in Q1 2016 and has held it in 29 quarters since. The position peaked at $11.2M in Q1 2026. 2,281 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Park Avenue Securities held 71,241 shares of Gilead Sciences worth $9M as of Q2 2026.
- Park Avenue Securities sold 9,174 Gilead Sciences shares in Q2 2026, an estimated $1.21M.
- Gilead Sciences made up 0.06% of Park Avenue Securities's portfolio in Q2 2026, its #256 holding.
- Park Avenue Securities first reported a position in Gilead Sciences in Q1 2016 and has held it in 29 quarters since.
- Park Avenue Securities's Gilead Sciences position peaked at $11.2M in Q1 2026.
- 2,281 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.